Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 13/20 | 0.79 |
| ▸ | RARG | P13631 | 13/20 | 0.79 |
| ▸ | RARA | P10276 | 11/20 | 0.79 |
| ▸ | CYP26A1 | O43174 | 5/20 | 0.67 |
| ▸ | CYP26B1 | Q9NR63 | 4/20 | 0.67 |
| ▸ | RXRA | P19793 | 5/20 | 0.62 |
| ▸ | RXRB | P28702 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | RXRG | P48443 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5888064 | 0.89 | RXRA (0.72) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL6372648 | 0.88 | RARB (1.00) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL10541551 | 0.87 | RARB (0.79) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL8950182 | 0.83 | RARB (0.79) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL2391376 | 0.81 | RARB (1.00) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL29462789 | 0.80 | RARA (0.74) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL2909591 | 0.80 | RARA (0.74) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL2331952 | 0.80 | RARB (1.00) | RARBRARGRARACYP26A1CYP26B1 | |
| SCHEMBL10544159 | 0.80 | RARB (0.79) | RARBRARGRARACYP26A1CYP26B1 | |
| Hydrazine SCHEMBL9430381 | 0.79 | RARB (0.76) | RARBRARGRARACYP26A1CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0220118-B1 | BICYCLIC NAPHTHALENIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND COSMETICS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1992-01-02 | — | — | EP | claimed |
| EP-1227791-B1 | USE OF AROMATIC POLYCYCLIC COMPOUNDS AS ACTIVATORS OF PPARS-TYPE RECEPTORS IN A COSMETIC OR PHARMACEUTICAL COMPOSITION | OREAL (FR) | 2006-11-08 | — | — | EP | disclosed |
| US-20050208001-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | SOCIETE L'OREAL, S.A. (FR) | 2005-09-22 | — | — | US | disclosed |
| US-20030013734-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | MAIGNAN JEAN (FR) | 2003-01-16 | — | — | US | disclosed |
| US-20020049250-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | SOCIETE L'OREAL, S.A. (FR) | 2002-04-25 | — | — | US | disclosed |
| US-4826969-A | SKIN AND EYE DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049250-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | PPARG, PPARA, PPARD | RARB 20/4885RARG 28/4885RARA 12/4885 |
| US-20030013734-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | PPARG, PPARA, PPARD | RARB 20/4885RARG 28/4885RARA 12/4885 |
| US-20050208001-A1 | PPAR receptor activator compounds for treating cutaneous disorders/afflictions | PPARG, PPARA, PPARD | RARB 23/4885RARG 28/4885RARA 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.